TABLE 1.
Baseline demographics and transient elastography characteristics
| COVID‐19 (n = 98) | LSM < 9.6 (n = 86) | LSM ≥ 9.6 (n = 12) | P | |
|---|---|---|---|---|
| Age, years | 55.2 ± 13.9 | 55.1 ± 14.4 | 58.1 ± 10.9 | .492 |
| Male sex | 58 (59.2) | 52 (60.5) | 6 (50.0) | .490 |
| Body‐mass index | 29.7 (20.1‐48.7) | 30.2 ± 5.1 | 33.7 ± 7.5 | .028* |
| Obesity | 47 (48.5) | 38 (44.7) | 9 (75.0) | .066 |
| Smoking | 9 (9.2) | 8 (9.3) | 1 (8.3) | .913 |
| Diabetes mellitus | 22 (22.4) | 16 (18.6) | 6 (50.0) | .015* |
| Hypertension | 38 (38.8) | 31 (36.0) | 7 (58.3) | .138 |
| Hyperlipidaemia | 5 (5.1) | 5 (5.8) | – | .391 |
| Heart disease | 13 (13.3) | 10 (11.6) | 3 (25.0) | .201 |
| Chronic lung disease | 14 (14.3) | 14 (16.3) | – | .131 |
| Chronic renal failure | 1 (1.2) | 1 (1.2) | – | .707 |
| Immunosuppression/Malignancy | 6 (6.2) | 6 (7.0) | – | .366 |
| Number of comorbidities | ||||
| 0 | 37 (37.8) | 35 (40.7) | 2 (16.7) | |
| 1 | 35 (35.7) | 30 (34.9) | 5 (41.7) | .231 |
| >1 | 26 (26.5) | 21 (24.4) | 5 (41.7) | |
| NAFLD (CAP > 274 dB/m) | 41(41.8) | 32 (37.2) | 9 (75.0) | .013* |
| LSM, kPA (VCTE) | 5.8 (2.6‐16.1) | 5.5 ± 1.6 | 11.6 ± 2.2 | <.001* |
| CAP, dB/m (VCTE) | 261.2 ± 57.6 | 255.2 ± 57.1 | 303.9 ± 42.3 | .002* |
| IQR (VCTE) | 31.5 ± 14.5 | 31.9 ± 14.3 | 28.2 ± 13.7 | .426 |
| IQR/median (VCTE) | 17 (3‐29) | 16.7 ± 7.5 | 18.1 ± 6.8 | .476 |
Abbreviations: CAP, controlled attenuation parameter; IQR, interquartile range; LSM, liver stiffness measurement; NAFLD, nonalcoholic fatty liver disease; VCTE, vibration‐controlled transient elastography.
*
P value < .05.